The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings

17 Jan 2017 15:30

RNS Number : 3933U
Diurnal Group PLC
17 January 2017
 

17 January 2017

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, received notification of the following purchase of shares by a person closely associated to a Company Director on 16 January 2017:

 

Mrs Lynne Raymond, wife of Alan Raymond, Non-executive Director, purchased 9,000 ordinary shares of 5.0 pence each in the Company ("Ordinary Shares") at a price of 110 pence per Ordinary Share. Following the transaction, Alan Raymond and his connected parties have a total interest of 22,888 Ordinary Shares, representing 0.04% of the total voting rights.

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Richard Bungay, CFO

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk 

 

 

DEALING NOTIFICATION FORM FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Lynne Ryamond

Reason for the notification

a)

Position/status:

Closely associated person to a Non-Executive Director

b)

Initial notification/Amendment:

Initial

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Diurnal Group plc

b)

LEI:

n/a

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

 

Identification code:

Ordinary shares of 5p each.

 

 

GB00BDB6Q760

b)

Nature of the transaction:

Purchase

c)

Price(s) and volume(s):

Price(s)

Volume(s)

 

110p

9,000

 

d)

Aggregated information:

Aggregated volume: 9,000

 

Price: £9,900.00

e)

Date of the transaction:

16 January 2017

f)

Place of the transaction:

XLON

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFFELTIDLID
Date   Source Headline
24th Dec 201512:18 pmRNSHolding(s) in Company
24th Dec 20158:00 amRNSAdmission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.